ClinicalTrials.gg
CompletedNCT04809363COMPASS-CDUpdated Oct 8, 2026

A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

A Phase 4 interventional study of CDPATH™ and Blood Draw in Crohn's Disease, sponsored by Takeda. Completed at 44 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Takeda · Phase 4, Interventional, and Diagnostic

How we know

Updated Oct 8, 2026Now CompletedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
241
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies in Crohn Disease by Takeda — 12 open to participants now, 14 under way, 7 of them phase 3. Crohn Disease · Takeda.

Enrollment
15th of 51
241 · median 100
Started
2021
with 14 others
Phase 4
10 of 86
1 open now
Registered
57th of 86
by date

Among the 86 studies in Crohn Disease by Takeda, this one is the 15th largest by enrollment of the 51 interventional ones that give a count, is one of 15 that started in 2021, is one of 10 in phase 4, and was the 57th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

12 of the 86 studies in Crohn Disease by Takeda are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Crohn Disease by Takeda, or all of them as a file.
02

Study summary

CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.

Read the detailed description

The tool being tested in this study is called CDPATH™. CDPATH™ is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH™.

The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH™ process and with their treatment choice.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
  2. Has agreed to use the CDPATH™ tool.
  3. Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.

Exclusion criteria

Exclusion Criteria:

  1. Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
  2. Has had any non-CD-related abdominal surgery.
  3. Has received biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
  4. Has previously used CDPATH™ or PROSPECT results to assess CD risk for complications.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
241 participants (actual)

Study arms

  • Experimental
    CDPATH™

    Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis.

    Other: CDPATH™ · Other: Blood Draw

Interventions

  • OtherCDPATH™

    Crohn's disease risk prediction tool.

    Also known as: PROSPECT

  • OtherBlood Draw

    Three blood samples will be drawn.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Real-world Practice in Each Risk Category at Baseline Based on the CDPATH™ Tool Results

    The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years.

    Time frame: Baseline (Day 1)

Secondary outcomes

  1. Percentage of Participants with Specific Treatment Path and Choice Based on CDPATH™ Tool, Stratified According to Risk Category

    Treatment path (i.e., sequence over time) and choice, by low, medium and high risk, will be chosen to characterize treatment path and choice based on risk stratification.

    Time frame: Up to 36 months

  2. Change From Baseline in Decisional Conflict Scale (DCS) Score

    DCS is a validated electronic patient-reported outcome (ePRO) collected via electronically administered patient surveys. It measures personal perceptions of the following responses: uncertainty in choosing options, modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making, and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. DCS involves answering 11 questions of PRO, of which 10 questions can be answered as yes (score = 0) or unsure (score = 2) or no (score =4). The total score will range from 0 to 40. Higher score indicates higher decisional conflict.

    Time frame: Baseline, then every 6 months up to 36 months

  3. Change From Baseline in Work Productivity and Activity Impairment Questionnaire - CD Version (WPAI-CD) Score

    WPAI-CD is a validated ePRO collected via electronically administered patient surveys. It consists of six questions that evaluate 4 domain scores: absenteeism (i.e., work time missed), presenteeism (i.e., reduced work productivity), overall work impairment, and activity impairment. Scores are expressed as a percentage of impairment, where higher scores indicate greater impairment and reduced productivity. The total score ranges from 0 (no impairment) to 100% (total loss of work productivity).

    Time frame: Baseline, then every 6 months up to 36 months

  4. Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale Score

    PROMIS Global Health scale is a validated ePRO collected via electronically administered patient surveys. It is a 10-item PRO measuring the overall evaluation of one's physical and mental health. The total score ranges from 0 to 100. The final score will be represented by the T-score metric, in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A higher PROMIS T-score represents more of the concept being measured (higher Global Health score indicate better health).

    Time frame: Baseline, then every 6 months up to 36 months

  5. Patient-Reported Satisfaction and Experience Score with the CDPATH™ Tool

    Participant's satisfaction and experience with the CDPATH™ tool will be assessed based on 15 questions. Negative responses/lower score to/in these questions indicates less satisfaction whereas positive responses/higher score indicates satisfaction with the tool.

    Time frame: Up to 36 months

  6. Number of Participants with Clinical Outcomes

    Participants with clinical outcomes describing the disease burden based on treatment path and controlling for risk strata will be reported.

    Time frame: Up to 36 months

  7. Percentage of Participants with Healthcare Resource Utilization

    Healthcare resource includes healthcare provider (HCP) visits/referrals, visit to emergency room, hospitalizations, surgery, new CD-related complications, and diagnostic evaluations (e.g., imaging, colonoscopy, etc.).

    Time frame: Up to 36 months

  8. Change from First Assessment in Health Care Provider (HCP)-reported Assessment of the Feasibility and Usability of the CDPATH™ Tool

    HCP-reported CDPATH™ satisfaction data will be collected directly from HCPs via electronically administered HCP surveys and entered into the eCRF. HCPs will be queried regarding their satisfaction and experience with the general process, the ease of incorporating the tool in their everyday practice, and the impact of the tool on their treatment recommendations and participant communications. For the 6 questions, HCP will rate on 1-5 scale where, 1=strongly disagree and 5=strongly agree. For remaining 4 questions, written feedback from HCP will be consider. Overall positive responses will indicate higher feasibility and usability.

    Time frame: First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

07

Study locations

44 sites
  • Arizona Arthritis & Rheumatology Research, PLLC
    Phoenix, Arizona 85032, United States
  • VA Loma Linda Healthcare System
    Loma Linda, California 92357, United States
  • United Medical Doctors
    Murrieta, California 92563, United States
  • University of Southern California Medical Center
    Newport Beach, California 92663, United States
  • Clinnova Research Solutions
    Orange, California 92868, United States
  • University of California at Irvine Medical Center
    Orange, California 92868, United States
  • Kaiser Permanate of Colorado
    Aurora, Colorado 80014, United States
  • Medical Research Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • West Central Gastroenterology d/b/a Gastro Florida
    Clearwater, Florida 33762, United States
  • Gastroenterology Associates of Pensacola, PA
    Pensacola, Florida 32503, United States
  • Grand Teton Research Group, PLL
    Idaho Falls, Idaho 83404, United States
  • GI Alliance
    Arlington Heights, Illinois 60005, United States
  • GI Alliance
    Gurnee, Illinois 60031, United States
  • Comprehensive Gastrointestinal Health
    Northbrook, Illinois 60062, United States
  • Rockford Gastroenterology Associates, Ltd.
    Rockford, Illinois 61107, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • Iowa Digestive Disease Center
    Clive, Iowa 50325, United States
  • University of Iowa Hospitals & Clinics
    Iowa City, Iowa 52242-1009, United States
  • University of Kansas Medical Center Research Institute, Inc.
    Kansas City, Kansas 66160, United States
  • GI Alliance - Baton Rouge
    Baton Rouge, Louisiana 70809, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71105, United States
  • Gastro Center of Maryland
    Columbia, Maryland 21045, United States
  • Lahey Clinic Inc. - PARENT ACCOUNT
    Burlington, Massachusetts 01805, United States
  • UMASS Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • University of New Mexico
    Albuquerque, New Mexico 87131-0001, United States
  • Lenox Hill Hospital
    New York, New York 10075-1850, United States
  • Clinical Inquest Center Ltd
    Beavercreek, Ohio 45431, United States
  • Dayton Gastroenterology, Inc
    Dayton, Ohio 45415, United States
  • The Oregon Clinic, P.C.
    Portland, Oregon 97220-9442, United States
  • Susquehanna Research Group, LLC
    Camp Hill, Pennsylvania 17011, United States
  • Allegheny Center for Digestive Health
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center Health System
    Pittsburgh, Pennsylvania 15213, United States
  • Frontier Clinical Research, LLC
    Uniontown, Pennsylvania 15401, United States
  • Palmetto Primary Care Physician Division of Gastroenterology
    Summerville, South Carolina 29486, United States
  • Rapid City Medical Center, LLC
    Rapid City, South Dakota 57701, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37204, United States
  • The University of Texas at Austin
    Austin, Texas 78712, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • GI Alliance - Southlake
    Southlake, Texas 76092, United States
  • Care Access Research Berkley
    Ogden, Utah 84403, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • GCGA Physicians LLC
    Fairfax, Virginia 22031, United States
  • Gastroenterology Associates
    Lynchburg, Virginia 24502, United States
  • GI Alliance
    Bellevue, Washington 98405, United States
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Aug 2026, 62 months.

Of 70 phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 68. This study's 62 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Sep 2026 → Aug 2026 and completion Sep 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2021
First posted
Mar 22, 2021
StartActual
Jun 25, 2021
Primary completionActual
Aug 27, 2026was Sep 2026
CompletionActual
Aug 27, 2026was Sep 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 30, 2026
Primary completion
Sep 12, 2026→Aug 27, 2026 (actual)
Sep 30, 2026
Study completion
Sep 12, 2026→Aug 27, 2026 (actual)
Sep 30, 2026
Enrollment
200 (estimated)→241
Oct 8, 2026
Show all 2 updates
  1. Oct 8, 2026
    Enrollment 243→241
    + 1 other change: verification date
  2. Sep 30, 2026
    Active, not recruiting→Completed
    Primary completion Sep 12, 2026→Aug 27, 2026 (now actual)
    Study completion Sep 12, 2026→Aug 27, 2026 (now actual)
    Enrollment 200 (estimated)→243 (actual)
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04809363
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 22, 2021
Start date
Jun 25, 2021
Primary completion
Aug 27, 2026
Completion
Aug 27, 2026
Last update
Oct 8, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion